Over the past year panCELLa has enhanced its patent position and expanded access to its exclusive FailSafeTM and induced Allogeneic Cell Tolerance (iACT Stealth CellsTM ). panCELLa continues to accelerate cell-based...
panCELLa, a privately held biotechnology company focused on developing safe therapeutic cell products for a broad range of diseases, is pleased to announce the issuance of the FailSafeTM patent in Japan. This patent is...
“Regenerative medicine is at a point now where we can translate our research into therapies that can help all humankind,” (Dr. Andras Nagy) Stem cell pioneer Andras Nagy has a way of describing the work of your...
panCELLa Inc. and its subsidiary, Implant Therapeutics, are pleased to announce their partnership with Angios Biotech to evaluate the efficacy of our technologies as incorporated into allogeneic vascular transplants deri...
panCELLa, a privately held biotechnology company focused on developing safe therapeutic cell products for a broad range of diseases, is pleased to announce the issuance of the FailSafeTM patent in Israel. This patent i...
Recently published (27 May 2021) in Nature Communications, a highly respected peer-reviewed scientific journal: Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants i...
"Hiding therapeutic cells (hypoimmunogenic or immune cloaked) from the immune system is intrinsically risky. Therefore, the development and use of these cells have to contain a system that replaces the missing tumour sur...
panCELLa, a privately held biotechnology company focused on developing safe therapeutic cell products for a broad range of diseases, is pleased to announce the first issuance of the FailSafeTM patent in Europe. This pa...
Licenses aim to accelerate drug discovery leading to development of new therapies PanCELLa agreement marks MilliporeSigma’s first CRISPR license for bioproduction “MilliporeSigma’s latest CRISPR licenses are th...
The inventors of panCELLa's exclusive induced Allogeneic Cell Tolerance have recently published a letter in CellStemCell. This letter is in response to Bryan J. González, et. all's "How Safe Are Universal Pluripotent...